MKTW vs. WGS, XPER, UWMC, MTC, API, INSE, FNGR, ALAR, MAPS, and AISP
Should you be buying MarketWise stock or one of its competitors? The main competitors of MarketWise include GeneDx (WGS), Xperi (XPER), UWM (UWMC), MMTec (MTC), Agora (API), Inspired Entertainment (INSE), FingerMotion (FNGR), Alarum Technologies (ALAR), WM Technology (MAPS), and Airship AI (AISP).
MarketWise (NASDAQ:MKTW) and GeneDx (NASDAQ:WGS) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.
MarketWise has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
MarketWise presently has a consensus price target of $3.50, suggesting a potential upside of 121.52%. GeneDx has a consensus price target of $18.00, suggesting a potential downside of 14.85%. Given MarketWise's higher probable upside, analysts plainly believe MarketWise is more favorable than GeneDx.
MarketWise has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than MarketWise, indicating that it is currently the more affordable of the two stocks.
In the previous week, MarketWise and MarketWise both had 3 articles in the media. MarketWise's average media sentiment score of 0.87 beat GeneDx's score of 0.73 indicating that MarketWise is being referred to more favorably in the media.
MarketWise received 23 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 65.00% of users gave MarketWise an outperform vote while only 42.86% of users gave GeneDx an outperform vote.
MarketWise has a net margin of 0.40% compared to GeneDx's net margin of -60.86%. MarketWise's return on equity of -0.67% beat GeneDx's return on equity.
23.0% of MarketWise shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 13.1% of MarketWise shares are owned by insiders. Comparatively, 28.1% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
MarketWise beats GeneDx on 11 of the 15 factors compared between the two stocks.
Get MarketWise News Delivered to You Automatically
Sign up to receive the latest news and ratings for MKTW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MKTW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MarketWise Competitors List
Related Companies and Tools
